EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intravenous immunoglobulin use in patients with unexplained recurrent pregnancy loss

Shorooq Banjar, Einav Kadour, Rabea Khoudja, Shaonie Ton-Leclerc, Coralie Beauchamp, Marc Beltempo, Michael H Dahan, Phil Gold, Isaac Jacques Kadoch, Wael Jamal, Carl Laskin, Neal Mahutte und 4 weitere

American Journal of Reproductive Immunology · 2023-08 · 90 (2)

DOI: 10.1111/aji.13737 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Reproductive Immunology, online erschienen am 20.06.2023. Verfasst von Shorooq Banjar und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Immunology and Allergy, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Abortion, Habitual. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Problem Recurrent pregnancy loss (RPL) affects up to 4% of couples attempting to conceive. RPL is unexplained in over 50% of cases and no effective treatments exist. Due to the immune system's pivotal role during implantation and pregnancy, immune‐mediated RPL may be suspected and immunomodulatory treatments like intravenous immunoglobulin (IVIg) have been administered but remain controversial. The goal of our study was to evaluate our center's 6 year‐outcomes and to develop a framework for IVIg use in RPL. Method of the study Retrospective, single‐center cohort study. All patients having received IVIg for unexplained RPL at the McGill Reproductive Immunology Clinic (MRIC) from January 2014 to December 2020 were included if maternal age was

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulins, IntravenousAbortion, HabitualPregnancyFemaleInfant, NewbornHumansAdultRetrospective StudiesCohort StudiesEmbryo Implantation

Stichwörter der Autor:innen

immunomodulatory therapyintravenous immunoglobulinunexplained recurrent pregnancy loss

Substanzen

Immunoglobulins, Intravenous

Autor:innen und Institutionen

  • Division of Clinical Immunology and Allergy, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Division of Clinical Immunology and Allergy, Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada.
  • Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Bnai-Zion Medical Center, Rishon-Le-Zion, Israel.
  • Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
  • Faculty of Medicine, McGill University, Montreal, Québec, Canada.
  • Ovo Clinic, Montréal, Québec, Canada.

Zitieren

APA

Banjar, S., Kadour, E., Khoudja, R., Ton-Leclerc, S., Beauchamp, C., Beltempo, M., Dahan, M. H., Gold, P., Jacques Kadoch, I., Jamal, W., Laskin, C., Mahutte, N., Reinblatt, S. L., Sylvestre, C., Buckett, W., & Genest, G. (2023). Intravenous immunoglobulin use in patients with unexplained recurrent pregnancy loss. American Journal of Reproductive Immunology, 90(2). https://doi.org/10.1111/aji.13737

Vancouver

Banjar S, Kadour E, Khoudja R, Ton-Leclerc S, Beauchamp C, Beltempo M, et al. Intravenous immunoglobulin use in patients with unexplained recurrent pregnancy loss. American Journal of Reproductive Immunology. 2023;90(2). doi:10.1111/aji.13737

BibTeX
@article{Banjar2023,
  author = {Banjar, Shorooq and Kadour, Einav and Khoudja, Rabea and Ton-Leclerc, Shaonie and Beauchamp, Coralie and Beltempo, Marc and Dahan, Michael H and Gold, Phil and Jacques Kadoch, Isaac and Jamal, Wael and Laskin, Carl and Mahutte, Neal and Reinblatt, Shauna Leigh and Sylvestre, Camille and Buckett, William and Genest, Genevieve},
  title = {Intravenous immunoglobulin use in patients with unexplained recurrent pregnancy loss},
  journal = {American Journal of Reproductive Immunology},
  year = {2023},
  volume = {90},
  number = {2},
  doi = {10.1111/aji.13737}
}
Kostenlos starten →